Literature DB >> 20350494

Control of HIV-1 replication in elite suppressors.

Joel N Blankson1.   

Abstract

HIV-1 infection usually results in high level of viral replication leading to a progressive decline of CD4+ T cells and eventually to full blown AIDS. Long term non-progressors (LTNPs) are patients who have stable CD4 counts for more than 5 years without antiretroviral therapy. Most of these patients have detectable levels of viremia and eventually will progress to AIDS. Elite controllers or suppressors (ES) represent a distinct subset of untreated patients who appear to be able to completely control viral replication. These patients maintain viral loads below the limit of detection of commercial assays for many years and generally do not show any clinical signs of disease progression. The mechanisms responsible for this remarkable control may lead to the design of effective HIV-1 vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20350494

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  35 in total

1.  Lack of association between HLA class II alleles and in vitro replication capacities of recombinant viruses encoding HIV-1 subtype C Gag-protease from chronically infected individuals.

Authors:  Jaclyn K Wright; Zabrina L Brumme; Boris Julg; Mary van der Stok; Zenele Mncube; Xiaojiang Gao; Jonathan M Carlson; Philip J R Goulder; Bruce D Walker; Mark A Brockman; Thumbi Ndung'u
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

2.  HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice.

Authors:  Maria Salgado; Michael D Swanson; Christopher W Pohlmeyer; Robert W Buckheit; Jin Wu; Nancie M Archin; Thomas M Williams; David M Margolis; Robert F Siliciano; J Victor Garcia; Joel N Blankson
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

Review 3.  Clinical development of candidate HIV vaccines: different problems for different vaccines.

Authors:  Stuart Z Shapiro
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-22       Impact factor: 2.205

4.  Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8+ T Cells.

Authors:  Abena K R Kwaa; Chloe A G Talana; Joel N Blankson
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

Review 5.  Dilemma of concepts and strategies for the prevention of spread of HIV in relation to human behavior, law and human rights.

Authors:  Reinhard H Dennin; Michael Lafrenz; Arndt Sinn; Lan-juan Li
Journal:  J Zhejiang Univ Sci B       Date:  2011-07       Impact factor: 3.066

6.  Immune Control of HIV.

Authors:  Muthukumar Balasubramaniam; Jui Pandhare; Chandravanu Dash
Journal:  J Life Sci (Westlake Village)       Date:  2019-06

Review 7.  The design and evaluation of HIV-1 vaccines.

Authors:  Kevin O Saunders; Rebecca S Rudicell; Gary J Nabel
Journal:  AIDS       Date:  2012-06-19       Impact factor: 4.177

8.  Breast-fed and bottle-fed infant rhesus macaques develop distinct gut microbiotas and immune systems.

Authors:  Amir Ardeshir; Nicole R Narayan; Gema Méndez-Lagares; Ding Lu; Marcus Rauch; Yong Huang; Koen K A Van Rompay; Susan V Lynch; Dennis J Hartigan-O'Connor
Journal:  Sci Transl Med       Date:  2014-09-03       Impact factor: 17.956

Review 9.  Cytokine production and dysregulation in HIV pathogenesis: lessons for development of therapeutics and vaccines.

Authors:  Morgan A Reuter; Carolina Pombo; Michael R Betts
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-27       Impact factor: 7.638

10.  Pressure from TRIM5α contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles.

Authors:  Clémence Granier; Emilie Battivelli; Camille Lécuroux; Alain Venet; Olivier Lambotte; Marion Schmitt-Boulanger; Constance Delaugerre; Jean-Michel Molina; Lisa A Chakrabarti; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.